Paul Matteis
Stock Analyst at Stifel
(1.85)
# 3,018
Out of 4,711 analysts
105
Total ratings
34.33%
Success rate
-9.88%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $397.27 | +24.35% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $16.98 | +88.46% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $5.61 | +6.95% | 5 | Dec 16, 2024 | |
| ALEC Alector | Downgrades: Hold | $4 | $1.86 | +115.05% | 4 | Dec 16, 2024 | |
| ANRO Alto Neuroscience | Maintains: Buy | $32 → $10 | $3.89 | +157.07% | 3 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Buy | $44 → $60 | $22.64 | +165.02% | 2 | Nov 12, 2024 | |
| ALKS Alkermes | Upgrades: Buy | $25 → $36 | $29.71 | +21.17% | 8 | Nov 5, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $115 → $87 | $65.66 | +32.50% | 8 | Sep 17, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $41 → $66 | $23.99 | +175.11% | 3 | Aug 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $18.07 | +93.69% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $35.63 | +48.75% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 → $295 | $245.44 | +20.19% | 13 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $16.87 | +24.48% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $13.50 | +114.81% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $135.42 | +6.34% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $146.47 | +95.94% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.28 | +218.47% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.50 | +380.00% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $10.85 | +139.63% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $3.63 | +561.16% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.58 | +768.06% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $8.36 | +282.78% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.70 | +1,311.76% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.85 | +1,359.46% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $6.85 | +279.56% | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $10.31 | +35.79% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $13.51 | +373.72% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $23.22 | +1,364.25% | 1 | Dec 21, 2016 |
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $397.27
Upside: +24.35%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $16.98
Upside: +88.46%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $5.61
Upside: +6.95%
Alector
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.86
Upside: +115.05%
Alto Neuroscience
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.89
Upside: +157.07%
Neurogene
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $22.64
Upside: +165.02%
Alkermes
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $29.71
Upside: +21.17%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $65.66
Upside: +32.50%
Dyne Therapeutics
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $23.99
Upside: +175.11%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $18.07
Upside: +93.69%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $35.63
Upside: +48.75%
Jun 27, 2024
Maintains: Buy
Price Target: $215 → $295
Current: $245.44
Upside: +20.19%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $16.87
Upside: +24.48%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $13.50
Upside: +114.81%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $135.42
Upside: +6.34%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $146.47
Upside: +95.94%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $6.28
Upside: +218.47%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.50
Upside: +380.00%
Oct 10, 2023
Initiates: Buy
Price Target: $26
Current: $10.85
Upside: +139.63%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $3.63
Upside: +561.16%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.58
Upside: +768.06%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $8.36
Upside: +282.78%
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $1.70
Upside: +1,311.76%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.85
Upside: +1,359.46%
Jul 20, 2021
Initiates: Buy
Price Target: $26
Current: $6.85
Upside: +279.56%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $10.31
Upside: +35.79%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $13.51
Upside: +373.72%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $23.22
Upside: +1,364.25%